

Veterinary Vaccine Market Forecasts to 2032 – Global Analysis By Type (Inactivated (Killed) Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, DNA Vaccines, Subunit Vaccines and Other Types), Animal, Disease, Technology, End User and By Geography

<https://marketpublishers.com/r/VDE10DEC1862EN.html>

Date: July 2025

Pages: 150

Price: US\$ 4,150.00 (Single User License)

ID: VDE10DEC1862EN

Abstracts

According to Statistics MRC, the Global Veterinary Vaccine Market is accounted for \$12.98 billion in 2025 and is expected to reach \$21.97 billion by 2032 growing at a CAGR of 7.8% during the forecast period. A veterinary vaccine is a biological preparation used to protect animals from specific infectious diseases by stimulating their immune systems. It contains antigens derived from pathogens such as viruses, bacteria, or parasites, which trigger an immune response without causing the disease itself. Veterinary vaccines are essential tools in preventing disease outbreaks, enhancing animal welfare, and improving food safety. They are widely used in both domestic pets and livestock to reduce the spread of zoonotic diseases, boost productivity, and decrease reliance on antibiotics in animal health management.

According to the National Bureau of Statistics China, China produced 57.94 million tonnes of pig meat in 2023, which represented a 5% increase from the previous year.

Market Dynamics:

Driver:

Rising prevalence of zoonotic diseases and livestock infections

The need for preventive measures to protect public health is growing as more diseases spread from animals to people. In order to protect animals and avoid financial losses due to disease outbreaks, livestock producers are spending money on vaccines. Vaccination programs are being promoted by governments and health organisations in an effort to curb the spread of illnesses. The need for updated and sophisticated vaccinations is further increased by the appearance of new disease strains. Innovation and growth in the veterinary vaccine sector are being driven by this increased urgency and awareness.

Restraint:

High cost and stringent regulatory approvals

Innovative vaccine development necessitates a large investment in cutting-edge technology and specialised knowledge. These costs frequently postpone product debuts and restrict access for smaller competitors. The intricacy is increased by strict regulatory approvals, which call for a great deal of safety and effectiveness testing. Time-to-market increases and innovation is discouraged by the drawn-out and expensive approval processes. All of these variables work together to limit the availability and growth of new veterinary vaccinations around the world.

Opportunity:

Advancements in vaccine technology and personalized animal care

Immune response is improved and adverse effects are decreased by innovations including vector-based vaccinations, mRNA-based vaccines, and recombinant DNA technologies. Faster reactions to newly developing zoonotic diseases are also made possible by these technologies. Demand for specialised vaccination plans based on species, breed, and health status is being driven by personalised animal care. Animal productivity and disease prevention are enhanced by this focused strategy. When taken as a whole, these dynamics greatly increase the market for veterinary vaccines' growth and relevance.

Threat:

Vaccine resistance and limited cold chain infrastructure in low-income regions

Cultural beliefs, misinformation, and doubts about the effectiveness of vaccines all play

a part in this resistance. Furthermore, inadequate cold chain infrastructure compromises the effectiveness of vaccinations by affecting how they are stored and transported. The problem is made worse by inadequate refrigeration equipment and an unstable electrical supply. Disease outbreaks and vaccination coverage decline as a result of these issues. As a result, the veterinary vaccine market's expansion and efficacy in these areas continue to be limited.

Covid-19 Impact

The COVID-19 pandemic moderately impacted the Veterinary Vaccine Market. While disruptions in supply chains and reduced veterinary visits during lockdowns temporarily hindered vaccine distribution and sales, the sector rebounded as pet adoption increased and awareness of animal health grew. Governments and stakeholders emphasized disease prevention in animals to avoid zoonotic outbreaks, driving demand for vaccines. Moreover, advancements in biotechnology and diagnostic tools, inspired by the pandemic, accelerated innovation in veterinary vaccine development, supporting market recovery and long-term growth.

The recombinant vaccines segment is expected to be the largest during the forecast period

The recombinant vaccines segment is expected to account for the largest market share during the forecast period, due to safer immunization solutions. These vaccines reduce the risk of reversion to virulence, enhancing animal safety and vaccine stability. They enable rapid development against emerging diseases, supporting timely responses to outbreaks. Their efficiency in inducing strong immune responses leads to reduced dosage frequency and improved compliance. Additionally, the growing adoption of advanced biotechnology in veterinary medicine fuels the demand for recombinant vaccines globally.

The homecare settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the homecare settings segment is predicted to witness the highest growth rate by enabling convenient and timely administration of vaccines, especially for companion animals. It reduces the need for frequent veterinary clinic visits, making preventive care more accessible and less stressful for pets and owners. Growing pet ownership and increasing awareness about animal health are driving demand for home-use vaccines and related services. Technological advancements like

easy-to-use vaccine delivery systems further support at-home administration. This shift enhances vaccination compliance and boosts overall market growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to increasing livestock populations, rising awareness of animal health, and supportive government initiatives. Countries like China, India, and Australia are witnessing increased demand for vaccines against foot-and-mouth disease, swine fever, and avian influenza. Expanding meat and dairy industries, along with improving veterinary infrastructure, further boost the market. However, challenges like regulatory barriers and limited cold chain logistics persist in rural areas.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to advanced animal healthcare systems, strong R&D investments, and a high focus on companion animal health. The U.S. and Canada lead in innovation and vaccine adoption, with widespread use of technologies like DNA and recombinant vaccines. Stringent regulatory frameworks ensure vaccine quality but also pose entry challenges for new products. Unlike Asia Pacific, pet insurance and veterinary service access significantly influence market dynamics, reflecting the region's mature and technology-intensive approach.

Key players in the market

Some of the key players profiled in the Veterinary Vaccine Market include Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Ceva Sante Animale, Elanco Animal Health, Virbac S.A., HIPRA, Phibro Animal Health Corporation, Vaxxinova International B.V., Biogenesis Bago, Hester Biosciences Limited, Indian Immunologicals Ltd., Neogen Corporation, Tianjin Ringpu Bio-Technology Co., Ltd., China Animal Husbandry Group, Jinyu Bio-technology Co., Ltd., Ourofino Saude Animal and Vetoquinol.

Key Developments:

In June 2025, Boehringer Ingelheim entered a strategic collaboration with Eko Health, a leader in AI-powered detection of heart and lung diseases, to improve heart murmur detection in dogs. This partnership combines BI's expertise in canine cardiology with Eko's digital stethoscope and AI algorithms. The collaboration aims to launch a canine-

specific heart murmur detection algorithm via an Eko mobile app in 2026, enhancing early diagnosis and care for canine heart disease.

In March 2025, Zoetis collaborated with the Federation of European Companion Animal Veterinary Associations (FECAVA) and the Federation of Veterinarians of Europe (FVE) to launch a handbook promoting best practices and policy recommendations to strengthen the human-animal bond. This initiative highlights Zoetis's commitment to advancing animal and human health through multi-stakeholder engagement.

In September 2024, Boehringer Ingelheim acquired Saiba Animal Health, a Swiss company specializing in therapeutic vaccines for companion animals. The acquisition brings SAH's virus-like particle vaccine platform into BI's R&D portfolio, targeting chronic diseases such as allergies, inflammation, and pain in pets. This move builds on previous collaborations between the companies and is expected to accelerate the development of innovative therapeutic vaccines with longer-lasting effects.

Types Covered:

Inactivated (Killed) Vaccines

Live Attenuated Vaccines

Toxoid Vaccines

Recombinant Vaccines

DNA Vaccines

Subunit Vaccines

Other Types

Animals Covered:

Companion Animals

Production Animals

Diseases Covered:

Canine Distemper

Rabies

Avian Influenza

Newcastle Disease

Brucellosis

Bovine Viral Diarrhea (BVD)

Other Diseases

Technologies Covered:

Conventional Vaccines

Advanced Vaccines

End Users Covered:

Veterinary Hospitals & Clinics

Livestock Farms

Homecare Settings

Research Institutes

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Technology Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL VETERINARY VACCINE MARKET, BY TYPE

- 5.1 Introduction
- 5.2 Inactivated (Killed) Vaccines
- 5.3 Live Attenuated Vaccines
- 5.4 Toxoid Vaccines
- 5.5 Recombinant Vaccines
- 5.6 DNA Vaccines
- 5.7 Subunit Vaccines
- 5.8 Other Types

6 GLOBAL VETERINARY VACCINE MARKET, BY ANIMAL

- 6.1 Introduction
- 6.2 Companion Animals
 - 6.2.1 Dogs
 - 6.2.2 Cats
- 6.3 Production Animals
 - 6.3.1 Cattle
 - 6.3.2 Swine
 - 6.3.3 Poultry
 - 6.3.4 Sheep & Goats

7 GLOBAL VETERINARY VACCINE MARKET, BY DISEASE

- 7.1 Introduction
- 7.2 Canine Distemper
- 7.3 Rabies
- 7.4 Avian Influenza
- 7.5 Newcastle Disease
- 7.6 Brucellosis
- 7.7 Bovine Viral Diarrhea (BVD)
- 7.8 Other Diseases

8 GLOBAL VETERINARY VACCINE MARKET, BY TECHNOLOGY

- 8.1 Introduction
- 8.2 Conventional Vaccines
- 8.3 Advanced Vaccines

9 GLOBAL VETERINARY VACCINE MARKET, BY END USER

- 9.1 Introduction
- 9.2 Veterinary Hospitals & Clinics
- 9.3 Livestock Farms
- 9.4 Homecare Settings
- 9.5 Research Institutes
- 9.6 Other End Users

10 GLOBAL VETERINARY VACCINE MARKET, BY GEOGRAPHY

- 10.1 Introduction
- 10.2 North America
 - 10.2.1 US
 - 10.2.2 Canada
 - 10.2.3 Mexico
- 10.3 Europe
 - 10.3.1 Germany
 - 10.3.2 UK
 - 10.3.3 Italy
 - 10.3.4 France
 - 10.3.5 Spain
 - 10.3.6 Rest of Europe
- 10.4 Asia Pacific
 - 10.4.1 Japan
 - 10.4.2 China
 - 10.4.3 India
 - 10.4.4 Australia
 - 10.4.5 New Zealand
 - 10.4.6 South Korea
 - 10.4.7 Rest of Asia Pacific
- 10.5 South America
 - 10.5.1 Argentina
 - 10.5.2 Brazil
 - 10.5.3 Chile
 - 10.5.4 Rest of South America
- 10.6 Middle East & Africa
 - 10.6.1 Saudi Arabia

- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa

11 KEY DEVELOPMENTS

- 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 11.2 Acquisitions & Mergers
- 11.3 New Product Launch
- 11.4 Expansions
- 11.5 Other Key Strategies

12 COMPANY PROFILING

- 12.1 Zoetis Inc.
- 12.2 Boehringer Ingelheim GmbH
- 12.3 Merck & Co., Inc.
- 12.4 Ceva Sante Animale
- 12.5 Elanco Animal Health
- 12.6 Virbac S.A.
- 12.7 HIPRA
- 12.8 Phibro Animal Health Corporation
- 12.9 Vaxxinova International B.V.
- 12.10 Biogenesis Bago
- 12.11 Hester Biosciences Limited
- 12.12 Indian Immunologicals Ltd.
- 12.13 Neogen Corporation
- 12.14 Tianjin Ringpu Bio Technology Co., Ltd.
- 12.15 China Animal Husbandry Group
- 12.16 Jinyu Bio technology Co., Ltd.
- 12.17 Ourofino Saude Animal
- 12.18 Vetoquinol

List Of Tables

LIST OF TABLES

- Table 1 Global Veterinary Vaccine Market Outlook, By Region (2024-2032) (\$MN)
- Table 2 Global Veterinary Vaccine Market Outlook, By Type (2024-2032) (\$MN)
- Table 3 Global Veterinary Vaccine Market Outlook, By Inactivated (Killed) Vaccines (2024-2032) (\$MN)
- Table 4 Global Veterinary Vaccine Market Outlook, By Live Attenuated Vaccines (2024-2032) (\$MN)
- Table 5 Global Veterinary Vaccine Market Outlook, By Toxoid Vaccines (2024-2032) (\$MN)
- Table 6 Global Veterinary Vaccine Market Outlook, By Recombinant Vaccines (2024-2032) (\$MN)
- Table 7 Global Veterinary Vaccine Market Outlook, By DNA Vaccines (2024-2032) (\$MN)
- Table 8 Global Veterinary Vaccine Market Outlook, By Subunit Vaccines (2024-2032) (\$MN)
- Table 9 Global Veterinary Vaccine Market Outlook, By Other Types (2024-2032) (\$MN)
- Table 10 Global Veterinary Vaccine Market Outlook, By Animal (2024-2032) (\$MN)
- Table 11 Global Veterinary Vaccine Market Outlook, By Companion Animals (2024-2032) (\$MN)
- Table 12 Global Veterinary Vaccine Market Outlook, By Dogs (2024-2032) (\$MN)
- Table 13 Global Veterinary Vaccine Market Outlook, By Cats (2024-2032) (\$MN)
- Table 14 Global Veterinary Vaccine Market Outlook, By Production Animals (2024-2032) (\$MN)
- Table 15 Global Veterinary Vaccine Market Outlook, By Cattle (2024-2032) (\$MN)
- Table 16 Global Veterinary Vaccine Market Outlook, By Swine (2024-2032) (\$MN)
- Table 17 Global Veterinary Vaccine Market Outlook, By Poultry (2024-2032) (\$MN)
- Table 18 Global Veterinary Vaccine Market Outlook, By Sheep & Goats (2024-2032) (\$MN)
- Table 19 Global Veterinary Vaccine Market Outlook, By Disease (2024-2032) (\$MN)
- Table 20 Global Veterinary Vaccine Market Outlook, By Canine Distemper (2024-2032) (\$MN)
- Table 21 Global Veterinary Vaccine Market Outlook, By Rabies (2024-2032) (\$MN)
- Table 22 Global Veterinary Vaccine Market Outlook, By Avian Influenza (2024-2032) (\$MN)
- Table 23 Global Veterinary Vaccine Market Outlook, By Newcastle Disease (2024-2032) (\$MN)

Table 24 Global Veterinary Vaccine Market Outlook, By Brucellosis (2024-2032) (\$MN)

Table 25 Global Veterinary Vaccine Market Outlook, By Bovine Viral Diarrhea (BVD) (2024-2032) (\$MN)

Table 26 Global Veterinary Vaccine Market Outlook, By Other Diseases (2024-2032) (\$MN)

Table 27 Global Veterinary Vaccine Market Outlook, By Technology (2024-2032) (\$MN)

Table 28 Global Veterinary Vaccine Market Outlook, By Conventional Vaccines (2024-2032) (\$MN)

Table 29 Global Veterinary Vaccine Market Outlook, By Advanced Vaccines (2024-2032) (\$MN)

Table 30 Global Veterinary Vaccine Market Outlook, By End User (2024-2032) (\$MN)

Table 31 Global Veterinary Vaccine Market Outlook, By Veterinary Hospitals & Clinics (2024-2032) (\$MN)

Table 32 Global Veterinary Vaccine Market Outlook, By Livestock Farms (2024-2032) (\$MN)

Table 33 Global Veterinary Vaccine Market Outlook, By Homecare Settings (2024-2032) (\$MN)

Table 34 Global Veterinary Vaccine Market Outlook, By Research Institutes (2024-2032) (\$MN)

Table 35 Global Veterinary Vaccine Market Outlook, By Other End Users (2024-2032) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Veterinary Vaccine Market Forecasts to 2032 – Global Analysis By Type (Inactivated (Killed) Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, DNA Vaccines, Subunit Vaccines and Other Types), Animal, Disease, Technology, End User and By Geography

Product link: <https://marketpublishers.com/r/VDE10DEC1862EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VDE10DEC1862EN.html>